IR-Med to present at National Pressure Injury Advisory Panel 2023
The company’s PressureSafe device is being designed to reduce healthcare disparity in pressure injury detection and treatment
Rosh Pina, Israel, March 14, 2023 (GLOBE NEWSWIRE) -- “IR-MED” or the “Company”) (OTCQB:IRME), will be presenting its proprietary technology that is being designed to detect early-stage Pressure Injuries (PI) at the Annual Conference of the National Pressure Injury Advisory Panel – NPIAP 2023. The presentation is part of a special Pre-Conference Workshop titled “Detecting Early Skin Changes in Dark Skin Tones.” The conference will take place on March 17-18 in San Diego, California.
Nearly $26.8B1 is spent each year on prevention and treatment of PI. Early PI detection can often be challenging for minority populations. According to this study2, patients with dark skin tones suffered more than twice as much as those with lighter skin, which evidences a major health inequity in the United States.
To address this gap in healthcare, IR-Med’s PressureSafe device, which is in advanced development stage, uses highly penetrating infrared light to “look” beneath the skin’s surface to sense biomarkers and structural changes in tissue layers. This data is then processed using artificial intelligence software to provide clinical feedback as a decision support system (DSS). The device is automatically recalibrated per each patient’s skin and tissue to create a personalized medical experience for each patient.
IR-Med was invited to NPIAP 2023 as part of the conference’s focus on equity in the prevention and treatment of pressure injuries. The Company will present the benefits of its unique “sense the invisible” technology on Thursday, March 16th and exhibit its product in Booth #108.
"We are honored to be recognized by NPIAP as a contributor to equity in healthcare,” said Moshe Gerber, CEO of IR-Med. “Our PressureSafe device is being designed to yield a robust and universally applicable solution that has the potential to serve a wide market and significantly reduce the burden and cost of PI-related treatment.”
IR-MED Inc., is developing a noninvasive spectrographic analysis technology platform, allowing healthcare professions to detect, measure and monitor, in real time, different molecules in the blood, in human tissue, and in body fluids without invasive procedures. The first product under development is a handheld optical monitoring device that is being developed to support early detection of pressure injuries (PI) to the skin and underlying tissue, regardless of skin tone as it calibrates personally to each patient's skin.
IR-MED's technology is being developed to allow accurate readings of biomarkers in a non-invasive method, that may provide caregiver the optimal decision support-system in cases where uncertainties disturb physicians in their decision processes.
IR-MED holds patents protecting its technology and innovations in the noninvasive tissue analysis, and in the modeling and analysis of subcutaneous tissue.
PressureSafe is currently undergoing usability studies at multiple medical centers. It is not yet available for commercial use. Expected US launch: H2/2023, pending relevant regulatory approvals.
Safe Harbor Statement / Forward-Looking Statements
Statements included in this press release, which are not historical in nature, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements relating to the future performance of IR-Med are subject to many factors including, but not limited to, the sufficiency or working capital and our ability to raise the capital needed to fund our development efforts, completion of the development and design of PressureSafe device, results of clinical/useability studies and trials, timing of product development, FDA approval/clearance of products in development, customer acceptance of our products in the market, the introduction of competitive products, the impact of any product liability or other adverse litigation, commercialization and technological difficulties, and the other risks identified in our most recent annual report on Form 10-K filed on March 31, 2022 with the Securities and Exchange Commission. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and we do not undertake any obligation to update any forward-looking statements, whether as a result of future events, new information, or otherwise.
Moshe Gerber, Chief Executive Officer
Tel: +972 (0) 4 6555054
Upcoming Life Sciences Events
- March 2023
- Zurich: Swiss Nordic Bio 2023
- April 2023
- Basel: Swiss Biotech Day 2023
- Brussels: Cell and Gene Therapy Summit
Latest company news
United Health Products Provides Update on FDA PMA Application Process
Novo Nordisk A/S - share repurchase programme
Oral semaglutide 25 mg and 50 mg demonstrate superior reductions in HbA1c and body weight versus 14 mg in people with type 2 diabetes in the PIONEER PLUS phase 3 trial